Effects of roflumilast in COPD patients receiving inhaled corticosteroid/long-acting β₂-agonist fixed-dose combination: RE²SPOND rationale and study design

References

• TashkinDPRoflumilast: the new orally active, selective phophodiesterase-4 inhibitor, for the treatment of COPDExpert Opin Pharma-cother20141518596
   PubMed Web of Science ®Google Scholar
• HatzelmannAMorcilloEJLungarellaGThe preclinical pharmacology of roflumilast – a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary diseasePulm Pharmacol Ther201023423525620381629
   PubMed Web of Science ®Google Scholar
• HeronMDeaths: Leading Causes for 2010. National Vital Statistics Reports626Hyattsville, MDNational Center for Health Statistics2013
   Google Scholar
• FordESMurphyLBKhavjouOGilesWHHoltJBCroftJBTotal and state-specific medical and absenteeism costs of COPD among adults aged ≥ 18 years in the United States for 2010 and projections through 2020Chest20151471314525058738
   PubMed Web of Science ®Google Scholar
• WoutersEFGroenewegenKHDentenerMAVernooyJHSystemic inflammation in chronic obstructive pulmonary disease: the role of exacerbationsProc Am Thorac Soc20074862663418073394
   PubMedGoogle Scholar
• YuAPYangHWuEQSetyawanJMocarskiMBlumSIncremental third-party costs associated with COPD exacerbations: a retrospective claims analysisJ Med Econ201114331532321500975
   PubMedGoogle Scholar
• WedzichaJABrillSEAllinsonJPDonaldsonGCMechanisms and impact of the frequent exacerbator phenotype in chronic obstructive pulmonary diseaseBMC Med20131118123945277
   PubMed Web of Science ®Google Scholar
• GrootendorstDCGauwSAVerhooselRMReduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPDThorax200762121081108717573446
   PubMed Web of Science ®Google Scholar
• CalverleyPMSanchez-TorilFMcIvorATeichmannPBredenbroekerDFabbriLMEffect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary diseaseAm J Respir Crit Care Med2007176215416117463412
   PubMed Web of Science ®Google Scholar
• CalverleyPMRabeKFGoehringUMKristiansenSFabbriLMMartinezFJM2-124 and M2-125 Study GroupsRoflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trialsLancet2009374969168569419716960
   PubMed Web of Science ®Google Scholar
• RennardSICalverleyPMGoehringUMBredenbrokerDMartinezFJReduction of exacerbations by the PDE4 inhibitor roflumilast – the importance of defining different subsets of patients with COPDRespir Res2011121821272339
   PubMed Web of Science ®Google Scholar
• Daliresp® (roflumilast tablets)US prescribing informationWilmington, DEAstraZeneca Pharmaceuticals LP2015
   Google Scholar
• FabbriLMCalverleyPMIzquierdo-AlonsoJLRoflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trialsLancet2009374969169570319716961
   PubMed Web of Science ®Google Scholar
• HananiaNACalverleyPMDransfieldMTPooled subpopulation analyses of the effects of roflumilast on exacerbations and lung function in COPDRespir Med2014108236637524120253
   PubMed Web of Science ®Google Scholar
• CazzolaMPiccioloSMateraMGRoflumilast in chronic obstructive pulmonary disease: evidence from large trialsExpert Opin Pharmacother201011344144920102307
   PubMed Web of Science ®Google Scholar
• DrummondMBDasenbrookECPitzMWMurphyDJFanEInhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysisJAMA2008300202407241619033591
   PubMed Web of Science ®Google Scholar
• MoodleyTWilsonSMJoshiTPhosphodiesterase 4 inhibitors augment the ability of formoterol to enhance glucocorticoid-dependent gene transcription in human airway epithelial cells: a novel mechanism for the clinical efficacy of roflumilast in severe chronic obstructive pulmonary diseaseMol Pharmacol201383489490623389862
   PubMed Web of Science ®Google Scholar
• MartinezFJCalverleyPMAGoehringU-MBroseMFabbriLMRabeKFEffect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trialLancet2015385997185786625684586
   PubMed Web of Science ®Google Scholar
• YangIAClarkeMSSimEHFongKMInhaled corticosteroids for stable chronic obstructive pulmonary diseaseCochrane Database Syst Rev20127Cd00299122786484
   PubMed Web of Science ®Google Scholar
• KewKMMavergamesCWaltersJALong-acting beta2-agonists for chronic obstructive pulmonary diseaseCochrane Database Syst Rev201310Cd01017724127118
   PubMed Web of Science ®Google Scholar
• CalverleyPMAndersonJACelliBSalmeterol and fluticasone propionate and survival in chronic obstructive pulmonary diseaseN Engl J Med2007356877578917314337
   PubMed Web of Science ®Google Scholar
• TashkinDPCelliBSennSA 4-year trial of tiotropium in chronic obstructive pulmonary diseaseN Engl J Med2008359151543155418836213
   PubMed Web of Science ®Google Scholar
• AaronSDVandemheenKLFergussonDTiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trialAnn Intern Med2007146854555517310045
   PubMed Web of Science ®Google Scholar
• CazzolaMPageCLong-acting bronchodilators in COPD: where are we now and where are we going?Breathe2014102110120
   Google Scholar
• RennardSThomashowBCrapoJIntroducing the COPD foundation guide for diagnosis and management of COPD, recommendations of the COPD foundationCOPD201310337838923713598
   PubMedGoogle Scholar
• ChenWThomasJSadatsafaviMFitzGeraldJMRisk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysisLancet Respir Med20153863163926208998
   PubMed Web of Science ®Google Scholar
• CalverleyPMMartinezFJFabbriLMGoehringUMRabeKFDoes roflumilast decrease exacerbations in severe COPD patients not controlled by inhaled combination therapy? The REACT study protocolInt J Chron Obstruct Pulmon Dis2012737538222791991
   PubMed Web of Science ®Google Scholar